Trial Profile
OPEN LABEL, PHASE II PILOT STUDY OF STI571 IN THE TREATMENT OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA PTCL REFRACTORY, RESISTANT OR NOT AMENABLE TO CONVENTIONAL THERAPY.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2011
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 01 Jun 2011 New trial record